About Electromedical Products International, Inc.
EPI is a leading neuromodulation therapeutic company specializing in non-invasive brain stimulation for psychiatric disorders and insomnia, along with microcurrent therapy for pain management, with devices for both clinical use and research.
A company is more than its product offerings. Our people are our most important resource.
When you invest in Alpha-Stim CES device technology—whether you’re a patient, a doctor seeking a safe, effective, approach to pain relief and mood and sleep treatment, or a distributor wishing to offer an advanced medical technology to the marketplace—you’re investing in a lot more than a medical device. Alpha-Stim technology is proven and is backed by decades of research; EPI fully supports its products and customers through ongoing research, education, and clinical support.
EPI is a global enterprise and has received regulatory approvals in numerous countries. Alpha-Stim products and accessories are FDA cleared in the United States for anxiety, insomnia, and pain, have obtained the CE mark for regulatory approval in Europe (through the European Medical Device Regulation), been awarded the UL (Underwriter’s Laboratory) safety listing, and are approved throughout most of the world.
News from EPI
Breakthrough Technology Proves Rapid Relief of Depression with Non-Invasive Brain Stimulation
Depression, a debilitating disorder affecting millions worldwide, may soon be treatable with an alarmingly effective, non-invasive brain stimulation technology. Researchers from the Department of Psychiatry at the University of North Carolina – Chapel Hill, in collaboration with Electromedical Products International, Inc. (EPI), have made a significant breakthrough in effectively treating depression in just five daily sessions.
An initial clinical trial, recently published in the American Journal of Psychiatry, demonstrated a pronounced reduction in symptom severity in people with major depressive disorder. Remarkably, 80% of patients were found to be free of clinical depression symptoms when assessed by a psychiatrist two weeks after completing treatment.
The technology works by delivering personalized brain stimulation in response to real-time measurements of brain activity, targeting a specific rhythmic electric activity pattern known to be disrupted in major depressive disorder. Researchers identified a strong correlation between successful modulation of the targeted electric brain activity and symptom reduction.
Dr. Flavio Frohlich, Professor of Psychiatry at UNC – Chapel Hill and Director of the Carolina Center for Neurostimulation, described the results as “stunning” and a potential “game changer” for millions of patients seeking better treatment options for their depression symptoms.
During each session, EPI’s device adjusts the mild electric waveform delivered to the patient based on the brain’s response to the stimulation. “You can imagine this technology as engaging in a dialogue with the brain,” says Dr. Frohlich, who also chairs EPI’s Scientific Advisory Board.
The study also highlighted how successful modulation of the targeted electric brain activity predicted symptom reduction, offering a promising new approach to treating this complex disorder.
“We are thrilled about these highly promising results and are eager to rapidly move forward with a double-blind, placebo-controlled study of this technology,” says Dr. Leah Townsend, Chief Science Officer of EPI. Brian Burke, President of EPI, adds, “We knew we had a winning technology when we first saw the results of this initial clinical trial. This breakthrough highlights the potential market impact of our closed-loop brain stimulation technology and reinforces our dedication to innovation.”
Contact Us
If you are interested in joining our team and would like to learn about possible employment opportunities, fill out the form below or contact us at alpha-stim@epii.com.
